cobitolimod
Nucleic acidexperimental
Clinical trial activity
4 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
2
Phase 4
0
Earliest trial started Dec 1, 2011 (NCT01493960)
Timeline
Indications
Studied for
Mechanism of action
- Toll-like receptor 9ACTIVATOR
TLR9 activator
- Toll-like receptor 9AGONIST
Toll-like receptor 9 agonist
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297564 ↗
Also known as
- cobitolimod
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05404074 | Phase 1 | Nov 22, 2021 | InDex Pharmaceuticals |
| NCT04985968 | Phase 3 | Nov 20, 2021 | Friedrich Alexander University, InDex Pharmaceuticals |
| NCT03178669 | Phase 2 | Jun 1, 2017 | Friedrich Alexander University, InDex Pharmaceuticals |
| NCT01493960 | Phase 3 | Dec 1, 2011 | InDex Pharmaceuticals, University of Nottingham |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| InDex Pharmaceuticals | For profit | 4 | 4 | 3 | 2011 |
| Friedrich Alexander University | Academic/Hospital | 2 | 0 | 2 | 2017 |
| University of Nottingham | Academic/Hospital | 1 | 0 | 1 | 2011 |
3 organizations
Page 1 / 1